Immunoglobulin G4 related disease Treatment

Navigating Treatment Options: From Symptom Control to Organ Protection

The primary goal of treating Immunoglobulin G4-related disease, often called IgG4-RD, is to prevent permanent organ damage while managing the inflammation that characterizes this condition. Because IgG4-RD is a fibro-inflammatory disorder—meaning it causes both inflammation and scarring in affected tissues—early and effective treatment is essential to preserve organ function. The disease often damages organs silently, sometimes for months or years, before a person experiences noticeable symptoms. By the time someone seeks medical attention, significant harm may have already occurred.1

Treatment approaches depend heavily on which organs are involved and how severe the disease has become. Someone with pancreatic involvement may need different management than someone whose disease primarily affects the salivary glands or kidneys. The stage of disease also matters: early, active disease typically requires more aggressive treatment, while patients in remission may need maintenance therapy to prevent flare-ups. Most patients with IgG4-RD have multiple organs affected at diagnosis, though one organ often dominates the clinical picture.2

Medical societies have developed clinical guidelines to help doctors make treatment decisions, though because IgG4-RD was only recognized as a distinct entity in the early 2000s, research continues to evolve. Standard treatments approved by regulatory authorities form the foundation of care, but scientists and clinicians are actively investigating new therapeutic approaches through clinical trials. These studies test whether newer medications might work better than traditional options or help patients who don't respond to standard therapy.3

The unpredictable nature of IgG4-RD means that treatment plans must remain flexible. Some patients experience dramatic improvements that last for years, while others face recurring flares that require adjustments to their medication regimen. The ultimate aim is achieving remission—a period when the disease shows no signs of activity—while minimizing the side effects and complications that can come with long-term treatment.

Standard Treatment: The Role of Glucocorticoids and Immunosuppression

Glucocorticoids, commonly known as steroids, have historically served as the cornerstone of IgG4-RD treatment. These powerful anti-inflammatory medications, with prednisone being the most frequently prescribed, work by suppressing the overactive immune response that drives tissue inflammation and damage. The response to glucocorticoids in IgG4-RD is often remarkably dramatic—so much so that some experts have suggested that a positive response to steroids could serve as a diagnostic criterion for the disease.1

When doctors initiate steroid therapy, they typically start with a moderate to high dose to quickly bring the inflammation under control. This initial phase aims to reduce organ swelling, shrink tumor-like masses, and prevent further tissue scarring. Nearly all patients with IgG4-RD show some response to glucocorticoids, with many experiencing significant reductions in the size of lesions and improvements in laboratory test results. Blood levels of IgG4, which are often elevated in this disease, may decrease with treatment, though this doesn't always correlate perfectly with clinical improvement.3

However, the initial success of glucocorticoids comes with important limitations. Studies show that approximately 40 percent of patients fail to achieve complete remission or experience a relapse within one year of starting treatment. The disease frequently recurs when steroids are tapered or discontinued, forcing many patients to remain on these medications for extended periods.3

Because of these concerns, doctors have increasingly turned to steroid-sparing approaches. One medication that has emerged as an excellent alternative is rituximab, a drug that targets a specific type of immune cell called B cells. Rituximab works by depleting B cells that express a protein called CD19 on their surface. These B cells are thought to directly drive the inflammation in IgG4-RD through the release of cytokines—proteins that affect immune system function—and may also activate other harmful immune cells.3

Rituximab offers several advantages over glucocorticoids. It typically doesn't cause the metabolic side effects associated with long-term steroid use, such as diabetes, high blood pressure, or bone thinning. Patients treated with rituximab can often reduce or eliminate their need for prednisone, which significantly improves quality of life. The medication is given intravenously, usually on day 1, day 15, and then at week 26, making it more convenient than daily oral steroids.4

The duration of treatment varies considerably among patients. Some achieve sustained remission after an initial course of therapy, while others require ongoing treatment or repeated cycles when the disease flares. Regular monitoring through blood tests, imaging studies, and clinical examinations helps doctors determine when medications can be reduced and when more aggressive treatment is needed. Close follow-up with physicians knowledgeable about IgG4-RD is essential, as this relatively rare condition requires specialized expertise for optimal management.3

Innovative Therapies in Clinical Trials: The Search for Better Options

Researchers are actively investigating several promising new treatments for IgG4-RD through clinical trials. These studies test whether novel medications can overcome the limitations of standard therapy, particularly for patients who don't respond adequately to glucocorticoids or who experience frequent disease relapses.

One of the most significant recent advances comes from the MITIGATE trial, a Phase 3 clinical study—the most advanced type of testing before a drug receives approval—that examined inebilizumab (marketed as Uplizna) in patients with active IgG4-RD. This randomized, double-blind, placebo-controlled trial enrolled 135 adults with active disease who received either intravenous inebilizumab or an inactive placebo on day 1, day 15, and week 26, then were followed for 52 weeks.4

Inebilizumab is a monoclonal antibody—a laboratory-created protein designed to mimic naturally occurring antibodies—that targets and destroys CD19-expressing B cells. While it works through a similar mechanism to rituximab, inebilizumab was specifically engineered for more complete B cell depletion. The mechanism of action focuses on eliminating the immune cells that produce IgG4 antibodies and drive the fibro-inflammatory process characteristic of this disease.4

The MITIGATE trial results were striking. Inebilizumab reduced the risk of disease flares by 87 percent compared to placebo. Of the 68 patients receiving inebilizumab, only seven experienced flares requiring treatment, compared to 40 of the 67 patients receiving placebo. Even more impressively, 58.8 percent of patients treated with inebilizumab achieved corticosteroid-free, flare-free complete remission at week 52, compared to just 22.4 percent of those receiving placebo. This means that more than half of patients treated with the new medication were able to stop taking steroids entirely while maintaining disease control.4

The safety profile of inebilizumab in the trial was generally consistent with its use in other conditions. The most common side effects were infections, including urinary tract infections, upper respiratory infections, and nasopharyngitis (inflammation of the nose and throat). Other frequently reported side effects included joint pain, back pain, and low levels of lymphocytes, a type of white blood cell important for immune function. These side effects were generally manageable and did not prevent most patients from continuing treatment.5

Based on these results, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of inebilizumab for treating adult patients with active IgG4-RD in September 2025. This recommendation represents a milestone, as it would make inebilizumab the first authorized treatment specifically for IgG4-RD in the European Union. The approval addresses a significant unmet medical need, particularly for older patients who are at higher risk for complications from long-term glucocorticoid use.5

Beyond inebilizumab, researchers are exploring other therapeutic approaches. Some clinical trials are investigating drugs that target different parts of the immune system or inflammatory pathways involved in IgG4-RD. For example, medications that block specific cytokines or target different types of B cells are under study. Scientists are also examining whether therapies that target plasmablasts—immature cells that develop into antibody-producing plasma cells—might be effective, since these cells appear to play a role in disease activity.6

Some trials are testing whether existing medications approved for other autoimmune conditions might benefit IgG4-RD patients. This approach, called drug repurposing, can potentially bring new treatments to patients more quickly since the safety profile of these medications is already established. However, because IgG4-RD is relatively rare and was only recently recognized as a distinct disease entity, clinical trials can be challenging to conduct and may take place at only a few specialized centers around the world.6

Patients interested in participating in clinical trials should discuss this option with their healthcare team. Trial participation offers potential access to cutting-edge treatments that aren't yet widely available, along with very close medical monitoring. However, it's important to understand that experimental therapies carry unknown risks, and some trial participants receive placebo rather than active medication. Eligibility criteria for trials are typically strict and may exclude patients with certain other health conditions or those taking specific medications.

Most common treatment methods

• Glucocorticoid therapy
  • Prednisone is the most commonly prescribed glucocorticoid for initial treatment
  • Nearly all patients respond to glucocorticoid therapy with dramatic improvement in symptoms and reduction of inflammatory masses
  • Typical treatment involves starting with moderate to high doses then gradually tapering
  • Approximately 40 percent of patients experience incomplete remission or relapse within one year
  • Long-term use causes significant side effects including diabetes, high blood pressure, osteoporosis, muscle weakness, and increased infection risk
• B cell-depleting therapy
  • Rituximab targets CD19-expressing B cells and has become an excellent alternative to glucocorticoids
  • Inebilizumab (Uplizna) is a newer monoclonal antibody that more completely depletes CD19-expressing B cells
  • These therapies reduce the need for long-term steroid use and avoid many glucocorticoid-related side effects
  • Administration is typically intravenous on day 1, day 15, and week 26
  • Common side effects include infections, joint pain, back pain, and temporary reduction in lymphocyte counts
• Immunosuppressive maintenance therapy
  • Used for patients who cannot taper off glucocorticoids or who experience frequent relapses
  • Aims to maintain disease remission while minimizing steroid exposure
  • Requires long-term commitment and regular monitoring for effectiveness and side effects